

World Journal of *Clinical Cases*

World J Clin Cases 2022 February 6; 10(4): 1140-1456



Contents

Thrice Monthly Volume 10 Number 4 February 6, 2022

REVIEW

- 1140 COVID-19: Gastrointestinal manifestations, liver injury and recommendations
Ozkurt Z, Çınar Tanrıverdi E

ORIGINAL ARTICLE

Retrospective Study

- 1164 Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
Qin ZQ, Yang SF, Chen Y, Hong CJ, Zhao TW, Yuan GR, Yang L, Gao L, Wang X, Lu LQ
- 1172 Sequential sagittal alignment changes in the cervical spine after occipitocervical fusion
Zhu C, Wang LN, Chen TY, Mao LL, Yang X, Feng GJ, Liu LM, Song YM
- 1182 Importance of the creation of a short musculofascial tunnel in peritoneal dialysis catheter placement
Lee CY, Tsai MK, Chen YT, Zhan YJ, Wang ML, Chen CC
- 1190 Clinical effect of methimazole combined with selenium in the treatment of toxic diffuse goiter in children
Zhang XH, Yuan GP, Chen TL
- 1198 Clinical study on the minimally invasive percutaneous nephrolithotomy treatment of upper urinary calculi
Xu XJ, Zhang J, Li M, Hou JQ

Observational Study

- 1206 Comparison of diagnostic validity of two autism rating scales for suspected autism in a large Chinese sample
Chu JH, Bian F, Yan RY, Li YL, Cui YH, Li Y
- 1217 Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia
Feng XD, Xie X, He R, Li F, Tang GZ

SYSTEMATIC REVIEWS

- 1226 What are the self-management experiences of the elderly with diabetes? A systematic review of qualitative research
Li TJ, Zhou J, Ma JJ, Luo HY, Ye XM

META-ANALYSIS

- 1242 Comparison of the clinical performance of i-gel and Ambu laryngeal masks in anaesthetised paediatric patients: A meta-analysis
Bao D, Yu Y, Xiong W, Wang YX, Liang Y, Li L, Liu B, Jin X

CASE REPORT

- 1255** Autogenous iliotibial band enhancement combined with tendon lengthening plasty to treat patella baja: A case report
Tang DZ, Liu Q, Pan JK, Chen YM, Zhu WH
- 1263** Sintilimab-induced autoimmune diabetes: A case report and review of the literature
Yang J, Wang Y, Tong XM
- 1278** Unicentric Castleman disease was misdiagnosed as pancreatic mass: A case report
Zhai HY, Zhu XY, Zhou GM, Zhu L, Guo DD, Zhang H
- 1286** Iguratimod in treatment of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: A case report
Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, Huang YC, Shen HL
- 1291** Primary central nervous system lymphoma presenting as a single choroidal lesion mimicking metastasis: A case report
Jang HR, Lim KH, Lee K
- 1296** Surgical treatment of acute cholecystitis in patients with confirmed COVID-19: Ten case reports and review of literature
Bozada-Gutiérrez K, Trejo-Avila M, Chávez-Hernández F, Parraguirre-Martínez S, Valenzuela-Salazar C, Herrera-Esquivel J, Moreno-Portillo M
- 1311** Hydrogen inhalation promotes recovery of a patient in persistent vegetative state from intracerebral hemorrhage: A case report and literature review
Huang Y, Xiao FM, Tang WJ, Qiao J, Wei HF, Xie YY, Wei YZ
- 1320** Ultrasound-guided needle release plus corticosteroid injection of superficial radial nerve: A case report
Zeng Z, Chen CX
- 1326** Inverted Y ureteral duplication with an ectopic ureter and multiple urinary calculi: A case report
Ye WX, Ren LG, Chen L
- 1333** Multiple miscarriages in a female patient with two-chambered heart and situs inversus totalis: A case report
Duan HZ, Liu JJ, Zhang XJ, Zhang J, Yu AY
- 1341** Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report
He ZD, Yang HY, Zhou SS, Wang M, Mo QL, Huang FX, Peng ZG
- 1349** Fatal rhabdomyolysis and disseminated intravascular coagulation after total knee arthroplasty under spinal anesthesia: A case report
Yun DH, Suk EH, Ju W, Seo EH, Kang H
- 1357** Left atrial appendage occlusion in a mirror-image dextrocardia: A case report and review of literature
Tian B, Ma C, Su JW, Luo J, Sun HX, Su J, Ning ZP

- 1366** Imaging presentation of biliary adenofibroma: A case report
Li SP, Wang P, Deng KX
- 1373** Multiple gouty tophi in the head and neck with normal serum uric acid: A case report and review of literatures
Song Y, Kang ZW, Liu Y
- 1381** Toxic epidermal necrolysis induced by ritodrine in pregnancy: A case report
Liu WY, Zhang JR, Xu XM, Ye TY
- 1388** Direct antiglobulin test-negative autoimmune hemolytic anemia in a patient with β -thalassemia minor during pregnancy: A case report
Zhou Y, Ding YL, Zhang LJ, Peng M, Huang J
- 1394** External penetrating laryngeal trauma caused by a metal fragment: A Case Report
Qiu ZH, Zeng J, Zuo Q, Liu ZQ
- 1401** Antegrade in situ laser fenestration of aortic stent graft during endovascular aortic repair: A case report
Wang ZW, Qiao ZT, Li MX, Bai HL, Liu YF, Bai T
- 1410** Hoffa's fracture in an adolescent treated with an innovative surgical procedure: A case report
Jiang ZX, Wang P, Ye SX, Xie XP, Wang CX, Wang Y
- 1417** Hemizygous deletion in the OTC gene results in ornithine transcarbamylase deficiency: A case report
Wang LP, Luo HZ, Song M, Yang ZZ, Yang F, Cao YT, Chen J
- 1423** Langerhans cell histiocytosis presenting as an isolated brain tumour: A case report
Liang HX, Yang YL, Zhang Q, Xie Z, Liu ET, Wang SX
- 1432** Inflammatory myofibroblastic tumor after breast prosthesis: A case report and literature review
Zhou P, Chen YH, Lu JH, Jin CC, Xu XH, Gong XH
- 1441** Eustachian tube involvement in a patient with relapsing polychondritis detected by magnetic resonance imaging: A case report
Yunaiyama D, Aoki A, Kobayashi H, Someya M, Okubo M, Saito K
- 1447** Endoscopic clipping for the secondary prophylaxis of bleeding gastric varices in a patient with cirrhosis: A case report
Yang GC, Mo YX, Zhang WH, Zhou LB, Huang XM, Cao LM

LETTER TO THE EDITOR

- 1454** Rituximab as a treatment for human immunodeficiency virus-associated nemaline myopathy: What does the literature have to tell us?
Gonçalves Júnior J, Shinjo SK

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Nicoleta-Monica Popa-Fotea, MD, PhD, Assistant Professor, Department of Cardio-thoracic, University of Medicine and Pharmacy, Bucharest 050474, Romania. nicoleta.popa-fotea@drd.umfcd.ro

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin, Production Department Director: Xu Guo, Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

February 6, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-cell lymphoma: A case report

Zhen-Dong He, Hai-Yan Yang, Sheng-Sheng Zhou, Man Wang, Qin-Li Mo, Feng-Xiang Huang, Zhi-Gang Peng

ORCID number: Zhen-Dong He 0000-0003-2843-6634; Hai-Yan Yang 0000-0002-5314-3676; Sheng-Sheng Zhou 0000-0003-2414-460X; Man Wang 0000-0002-6582-4487; Qin-Li Mo 0000-0003-3842-5605; Feng-Xiang Huang 0000-0002-7525-7332; Zhi-Gang Peng 0000-0001-7408-9237.

Author contributions: He ZD, Yang HY, and Peng ZG contributed to the data analysis and interpretation and manuscript writing; He ZD and Peng ZG contributed to the conception and design; He ZD, Yang HY, Zhou SS, Wang M, Mo QL, and Huang FX contributed to the collection and assembly of data; Peng ZG contributed to the administrative support and final approval of the manuscript; all authors have read and approved the final manuscript.

Informed consent statement: We obtained the patient's written informed consent to publish the details of their cases and the associated images.

Conflict-of-interest statement: The authors declare that there were no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and

Zhen-Dong He, Hai-Yan Yang, Sheng-Sheng Zhou, Man Wang, Qin-Li Mo, Feng-Xiang Huang, Zhi-Gang Peng, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China

Corresponding author: Zhi-Gang Peng, MD, PhD, Chief Doctor, Professor, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang Yong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. pengzhigang@gxmu.edu.cn

Abstract

BACKGROUND

Traditional chemotherapy has benefited many patients with non-Hodgkin's lymphoma, but results in a very poor response in patients with rare lymphomas or refractory lymphomas. Previous studies have shown that chidamide has potential anti-lymphoma activity and reverses lymphoma cell chemoresistance to increase the chemosensitivity of lymphoma cells to traditional chemotherapy.

CASE SUMMARY

A 14-year-old boy was admitted to our hospital with a 5-d history of generalized erythema, papules, and blisters. Initially, the disease was refractory to potent anti-allergic and anti-infective treatment, and his condition progressively worsened. Skin biopsy revealed primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-cell lymphoma. Considering that the disease is extremely rare in clinical practice, existing case reports have shown poor efficacy with traditional chemotherapy alone. We recommend chidamide combined with traditional chemotherapy for treatment. The regimen was as follows: Chidamide 30 mg/biw, cyclophosphamide 1100 mg/d1, pirarubicin 70 mg/d1, vincristine 2 mg/d1, dexamethasone 20 mg/d1-5, etoposide 100 mg/d1-5, in a 21 d cycle. The treatment effect was considerable, and complete remission was achieved after 4 cycles of treatment, after which the patient completed a total of 6 cycles of treatment. Subsequently, the patient regularly took chidamide 20 mg/biw as maintenance therapy for 1 year. To date, the patient has been disease-free for 3 years.

CONCLUSION

This case suggests that the combination of chidamide and traditional chemotherapy is effective in primary cutaneous aggressive epidermotropic CD8⁺

revised according to the CARE Checklist (2016).

Supported by the China Anti-Cancer Association Project, No. CORP-117.

Country/Territory of origin: China

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Received: August 5, 2021

Peer-review started: August 5, 2021

First decision: November 6, 2021

Revised: November 11, 2021

Accepted: December 25, 2021

Article in press: December 25, 2021

Published online: February 6, 2022

P-Reviewer: Ferreira GSA

S-Editor: Liu JH

L-Editor: Webster JR

P-Editor: Liu JH



cytotoxic T-cell lymphoma.

Key Words: Chidamide; Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma; Traditional chemotherapy; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The long-term efficacy of traditional chemotherapy in the treatment of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma is poor, and the main mechanism is the emergence of chemoresistance in lymphoma cells. Chidamide induces apoptosis and growth arrest of lymphoid and hematologic tumor cells and enhances the sensitivity of lymphoma cells to traditional chemotherapy. This case suggests that chidamide may enhance the efficacy of traditional chemotherapy, and that chidamide combined with traditional chemotherapy may be a promising treatment option for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.

Citation: He ZD, Yang HY, Zhou SS, Wang M, Mo QL, Huang FX, Peng ZG. Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report. *World J Clin Cases* 2022; 10(4): 1341-1348

URL: <https://www.wjgnet.com/2307-8960/full/v10/i4/1341.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i4.1341>

INTRODUCTION

Primary cutaneous aggressive epidermotropic CD8+ cytotoxic cell T-cell lymphoma is a rare subtype of cutaneous T-cell lymphoma, accounting for less than 1% of all cutaneous T-cell lymphomas. Only dozens of cases have been reported worldwide, and there is no optimal treatment. According to existing reports, the majority of patients with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma currently receive doxorubicin-based traditional chemotherapy. There are case reports of treatment with CHOP, CHOPE, and Hy-CVAD regimens, but the efficacy is poor. All result in short-term benefits, with an overall survival of 12-32 mo [1]. The main reason for the poor long-term efficacy of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma to traditional chemotherapy is that lymphoma cells are prone to chemoresistance [2]. Chidamide has potential anti-hematological tumor activity and enhances the chemosensitivity of lymphoma cells. It has been recognized for the treatment of relapsed or refractory peripheral T-cell lymphoma. Based on the above theory, we boldly tried the combination of chidamide with traditional chemotherapy (CHOPE) in a patient with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma with promising results.

CASE PRESENTATION

Chief complaints

A 14-year-old boy was admitted to the Department of Dermatology with a 5-d history of generalized erythema, papules, and blisters and was transferred to the Department of Medical Oncology.

History of present illness

The patient had generalized erythema, papules, and blisters with itching since August 18, 2017. Three days after the onset of symptoms, some blisters formed blood blisters with tan crusts on the surface, accompanied by pain, and fever, fear of cold, and chills, with a maximum body temperature of 41 °C.

Physical examination

The patient's body temperature was 37.8 °C, heart rate was 110 bpm, respiratory rate

was 20 breaths/min, and blood pressure was 99/67 mmHg. Scattered blood blisters were observed throughout the body, with the most severe blood blisters on the trunk, consistent with the distribution of skin transverse striae (Figure 1). Erosive surfaces of varying sizes were seen in the oral cavity, trunk, extremities, and perineum. Physical examination of the heart, lungs, and abdomen was unremarkable.

Laboratory examinations

After admission, a blood test was performed and the patient's white blood cell count was $5.86 \times 10^9/L$, hemoglobin concentration was 146.70 g/L, and platelets were $129.80 \times 10^9/L$. His biochemical results were as follows: Total protein, 61.2 g/L; albumin, 29.5 g/L; creatinine, 54 $\mu\text{mol/L}$; lactate dehydrogenase, 351 U/L; β -2 microglobulin, 3.6 mg/L; interleukin-6, 13.34 pg/mL. The results of bone marrow biopsy showed slight microscopic bone marrow hyperplasia, cell volume accounted for 40%, tertiary hematopoietic cells were present, granulocyte/erythrocyte ratio was slightly increased, and cell morphology was normal (Figure 2A). The skin of the left thigh was biopsied, and the pathology results indicated primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (Figure 2B). The results of immunohistochemistry revealed the following: CD3 (+), CD2 (-/+), CD4 (-/+), CD5 (-/+), CD7 (+), CD8 (+ +), CD56 (-), TiA-1 (+), GB (+), ALK (-), CD30 (-), CD20 (-), and CD10 (-); EBERs (-); TCR- γ gene rearrangement (-).

Imaging examinations

Positron emission tomography/computed tomography (PET/CT) showed mildly increased systemic cutaneous glucose metabolism, which was considered to be cutaneous lymphoma. Mild systemic skin swelling and a diffuse mild increase in glucose metabolism, especially in the local skin of both armpits, right upper quadrant, and posterior coccyx were observed (Figure 3). Multiple small lymph nodes of different sizes with increased glucose metabolism were observed in both armpits and groins.

FINAL DIAGNOSIS

Based on pathological biopsy, laboratory examinations, imaging examination and clinical manifestations, the patient was finally diagnosed with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.

TREATMENT

The patient was diagnosed more than 20 d after the onset of symptoms, and chidamide combined with CHOPE regimen was administered as the patient's first cycle of treatment as follows: Chidamide 30 mg/biw, cyclophosphamide 1100 mg/d1, doxorubicin 70 mg/d1, vincristine 2 mg/d1, dexamethasone 20 mg/d1-5, etoposide 100 mg/d1-5, in a 21 d cycle. The patient completed a total of 6 cycles of treatment and subsequently entered maintenance therapy.

OUTCOME AND FOLLOW-UP

After 4 cycles of treatment, the patient returned to the hospital for follow-up, and his skin rash on the face, neck, trunk, and extremities had disappeared (Figure 4A). The blood tests showed that the white blood cell count was $6.14 \times 10^9/L$, hemoglobin concentration was 123 g/L, and platelets were $225 \times 10^9/L$. His biochemical results were as follows: Total protein, 68.2 g/L; albumin, 36 g/L; creatinine, 60 $\mu\text{mol/L}$; lactate dehydrogenase, 225 U/L; β -2 microglobulin 1.96 mg/L; interleukin-6, 5.3 pg/mL. PET/CT showed that after chemotherapy for cutaneous lymphoma, the original lesions were inactivated and no new lesions were observed (Deauville score: 1 point). No clear structural or glucose metabolism abnormalities were noted (Figure 3B). Complete remission was observed. The patient had grade III bone marrow suppression during the 5th cycle of chemotherapy, and continued to complete chemotherapy as planned after repeated blood tests were normal after leukocyte-elevating therapy. After completing 6 cycles of treatment, he regularly took chidamide 20 mg/biw as maintenance therapy for 1 year. No significant hematological toxicity or



Figure 1 Photographs of skin lesions before treatment. Scattered blood blisters were observed throughout the body, with the most severe blood blisters on the trunk, consistent with the distribution of skin transverse striae.

gastrointestinal adverse events occurred during maintenance therapy with chidamide. The last follow-up was performed 2 wk ago and the patient's condition was stable without recurrence (Figure 4B).

DISCUSSION

Primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-cell lymphoma was first reported as a rare histopathological subtype of cutaneous T-cell lymphoma in 1999 by Berti *et al*[3]. It was first classified as a non-specific provisional entity by the World Health Organization/European Organization for Research and Treatment of Cancer in 2005[4]. This type of lymphoma is characterized by the presence of localized or diffuse papules, nodules, or tumors, which present as central ulceration or necrosis, or plaques with surface hyperkeratosis[5]. Primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-cell lymphoma is highly aggressive and can rapidly spread to various organs, such as the lungs, testes, central nervous system, or oral mucosa, with a poor response to traditional chemotherapy[6]. Some patients can benefit from doxorubicin-based multiagent chemotherapy for a short time, but most patients relapse a short time after treatment and even develop resistance to traditional chemotherapy and then it transforms into relapsed or refractory lymphoma. Treatment is still a great clinical challenge.

Primary cutaneous aggressive epidermotropic CD8⁺ cytotoxic T-cell lymphoma is clinically heterogeneous, and its course progresses rapidly. Treatment options for advanced disease are limited, and significantly effective treatment options deserve active exploration. Numerous studies have shown that histone deacetylase inhibitors (HDAC inhibitors) are used to treat malignant tumors, such as cutaneous T-cell lymphoma and peripheral T-cell lymphoma. Moreover, HDAC inhibitors are now




Figure 2 Bone marrow and skin biopsies. A: Bone marrow biopsy. Slight microscopic bone marrow hyperplasia, cell volume accounted for 40%, tertiary hematopoietic cells were present, granulocyte/erythrocyte ratio was slightly increased, and cell morphology was normal; B: Skin biopsy of left thigh. There was hyperkeratosis of the skin epidermis, hemorrhage in the papilla of the dermis, and local or diffuse small lymphocyte infiltration in both the epidermis and subcutaneously.




Figure 3 The patient underwent positron emission tomography/computed tomography before treatment and reexamination after 4 cycles of treatment. A: Positron emission tomography/computed tomography (PET/CT) before treatment. The figure showed mild systemic skin swelling and diffuse mild increase in glucose metabolism, especially in the local skin of both armpits, right upper quadrant, and posterior coccyx. Multiple small lymph nodes of different sizes with increased glucose metabolism were observed in both armpits and groins; B: PET/CT after treatment. The figure showed no clear structural or glucose metabolism abnormalities.

increasingly being used in combination with other types of anticancer drugs for the treatment of various malignancies. Chidamide is an innovative drug independently developed in China, which can exert anti-tumor activity by reversing tumor cell resistance, increasing tumor cell chemosensitivity, potentially regulating immunity and potential direct anti-tumor effects[7,8]. In December 2014, chidamide was approved by




Figure 4 Follow-up photographs of the patient. A: Photographs of the patient after completion of 4 treatment cycles. Generalized scattered blood blisters disappeared, and residual scattered skin pigmentation was observed; B: Photographs of the last follow-up. No abnormal lesions were observed.

China Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma. Previous studies have shown that chidamide can induce apoptosis and growth arrest of lymphoid or hematologic tumor cells, and can also reverse tumor cytochemical resistance to increase tumor cell chemosensitivity. Wei Guan *et al*[9] retrospectively analyzed 17 cases of refractory or relapsed T-lymphocytic lymphoma/leukemia (T-LBL/ALL) and found that chidamide has pleiotropic regulatory immune function and can enhance the sensitivity of tumor cells to chemotherapeutic drugs. Jiang *et al*[10] found that chidamide inhibited the proliferation and induced apoptosis of tumor cells and exerted potential anti-leukemia activity. Chidamide can also increase the chemosensitivity of tumor cells by disrupting the Smo/gli-1 pathway and the downstream signaling target p-AKT. Yan *et al*[8] found that the combination of chidamide and syndilimab enhanced the efficacy of syndilimab in NK/T cell lymphoma. Based on the above theory, we speculate that a treatment regimen combining chidamide may be a promising therapeutic strategy for refractory T-cell lymphoma. Common adverse events of chidamide include thrombocytopenia, leukopenia, neutropenia, QTc prolongation, fatigue, fever, and gastrointestinal symptoms. Studies have shown that the incidence of adverse events is low and easily controlled, with only a few patients discontinuing treatment due to serious adverse events[7,11].

The present patient with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma achieved complete remission following treatment with chidamide combined with CHOP regimen. On the one hand, this may have been due to the potential antitumor activity of chidamide, and on the other hand, it may have been because chidamide reverses tumor cell chemoresistance to increase tumor cell

chemosensitivity. In this case, the patient experienced short-term hematological toxicity during chemotherapy with chidamide combined with CHOPE regimen, but recovered quickly after leukocyte-elevating therapy. The patient successfully completed 6 cycles of therapy. In addition, no significant adverse events occurred in this patient during maintenance therapy. This regimen was well tolerated and provides a promising therapeutic strategy for the treatment of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.

CONCLUSION

In conclusion, we found that a combination of chidamide and a traditional chemotherapy regimen is a safe and effective treatment for primary cutaneous aggressive epidermotropic CD8+ cytotoxic cell T-cell lymphoma, but its long-term efficacy requires further evaluation. For patients with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma refractory to traditional therapy (*e.g.*, CHOP), we recommend early combination therapy with chidamide. This study also had limitations: Due to the rarity of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, analysis of the results obtained in this report requires caution. Whether the good efficacy in this patient was the result of synergy between traditional chemotherapy and chidamide or a separate effect of chidamide cannot be determined. In the future, we will continue to collect data to assess the efficacy and safety of chidamide in combination with CHOPE in patients with primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma.

ACKNOWLEDGEMENTS

We sincerely thank the chief editor and all review experts for reviewing this paper.

REFERENCES

- 1 **Guitart J**, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. *Mod Pathol* 2017; **30**: 761-772 [PMID: 28128277 DOI: 10.1038/modpathol.2016.240]
- 2 **Nofal A**, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. *J Am Acad Dermatol* 2012; **67**: 748-759 [PMID: 22226429 DOI: 10.1016/j.jaad.2011.07.043]
- 3 **Berti E**, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. *Am J Pathol* 1999; **155**: 483-492 [PMID: 10433941 DOI: 10.1016/S0002-9440(10)65144-9]
- 4 **Willemze R**, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005; **105**: 3768-3785 [PMID: 15692063 DOI: 10.1182/blood-2004-09-3502]
- 5 **Sundram U**. Cutaneous Lymphoproliferative Disorders: What's New in the Revised 4th Edition of the World Health Organization (WHO) Classification of Lymphoid Neoplasms. *Adv Anat Pathol* 2019; **26**: 93-113 [PMID: 30199396 DOI: 10.1097/PAP.0000000000000208]
- 6 **Slater DN**. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. *Br J Dermatol* 2005; **153**: 874-880 [PMID: 16225594 DOI: 10.1111/j.1365-2133.2005.06905.x]
- 7 **Shi Y**, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. *Ann Oncol* 2015; **26**: 1766-1771 [PMID: 26105599 DOI: 10.1093/annonc/mdv237]
- 8 **Yan Z**, Yao S, Liu Y, Zhang J, Li P, Wang H, Chu J, Zhao S, Yao Z. Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review. *Front Oncol* 2020; **10**: 608304 [PMID: 33363038 DOI: 10.3389/fonc.2020.608304]
- 9 **Guan W**, Jing Y, Dou L, Wang M, Xiao Y, Yu L. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia. *Leuk Lymphoma* 2020; **61**: 855-861

- [PMID: 31755348 DOI: 10.1080/10428194.2019.1691195]
- 10 **Jiang X**, Jiang L, Cheng J, Chen F, Ni J, Yin C, Wang Q, Wang Z, Fang D, Yi Z, Yu G, Zhong Q, Carter BZ, Meng F. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. *J Transl Med* 2021; **19**: 117 [PMID: 33743723 DOI: 10.1186/s12967-021-02789-3]
 - 11 **Moskowitz AJ**, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. *Leuk Lymphoma* 2017; **58**: 1306-1319 [PMID: 27813438 DOI: 10.1080/10428194.2016.1247956]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

